Advertisement


Toni K. Choueiri, MD, FASCO, on RCC: Biomarker Analysis From the CLEAR Trial

2024 ASCO Annual Meeting

Advertisement

Toni K. Choueiri, MD, FASCO, of the Dana-Farber Cancer Institute, discusses phase III findings showing that, in patients with advanced renal cell carcinoma (RCC), the benefit of lenvatinib plus pembrolizumab vs sunitinib in overall response rate does not appear to be affected by such factors as geneexpression signatures for tumorinduced proliferation, PDL1 status, or the mutation status of RCC driver genes.



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
The KEYNOTE study is actually the study that established first-line combination VEGF-TKI, lenvatinib, and PD-1 inhibitor, pembrolizumab, as a standard therapy in metastatic renal cell cancer. The study has met several endpoint, progression-free survival, overall survival, and response rate showing that the combination of pembrolizumab and lenvatinib is superior to sunitinib. And here, what we did during the 2024 ASCO, great meeting by the way, we looked at baseline PD-L1 expression by immunohistochemistry, specific gene alteration by interrogating whole exome, and gene expression pattern using RNA-Seq. We did not have samples on all the patient from the full analysis, but the large subset we had on had similar baseline characteristic as the whole cohort. What we concluded is the combination of lenvatinib and pembrolizumab does work irrespective of PD-L1 immunohistochemistry. It showed that it worked and had a longer progression-free survival and improved response rate over sunitinib regardless of specific kidney cancer driver gene alteration, and these driver gene alteration are essentially the top mutated gene in kidney cancer, VHL, PBRM1, [inaudible 00:01:37], BAP1, KDM5C, but the combination is superior to sunitinib irrespective. And finally, we did look at a specific molecular subtype and gene expression, but the gene expression where the past several years reported specific to renal cell or not, but we looked at specific signature for renal cell cancer, the clusters, and universally, it showed that pembrolizumab-lenvatinib does work irrespective of any molecular subtypes, whether it's the angiogenesis subtype, the immune proliferative, et cetera. We will continue trying to find biomarkers specific to one therapy, and despite that this is a bit on the negative side, I think it's important to show that what doesn't work as biomarker as important show what does work.

Related Videos

Gynecologic Cancers

Katherine C. Fuh, MD, PhD, on Ovarian Cancer: New Data on Batiraxcept and Paclitaxel

Katherine C. Fuh, MD, PhD, of the University of California, San Francisco, discusses phase III findings of the AXLerate-OC trial, showing that batiraxcept with paclitaxel compared to paclitaxel alone improved progression-free and overall survival in patients with platinum-resistant recurrent ovarian cancer whose tumors were AXL-high in an exploratory analysis (LBA5515).

Gynecologic Cancers

Alex Andrea Francoeur, MD, on Endometrial Cancer and Obesity Trends

Alex Andrea Francoeur, MD, of UC Irvine Health, discusses data showing an association between the increasing incidence of endometrial cancer and obesity, which disproportionately affects younger women and women of color. According to Dr. Francoeur, the findings warrant targeted health services and public health interventions to stabilize and ultimately reverse the rising rates (Abstract 5507).

Lung Cancer

Minesh P. Mehta, MD, on NSCLC: Tumor Treating Fields for Brain Metastases

Minesh P. Mehta, MD, of Miami Cancer Institute, part of Baptist Health South Florida, discusses results from the METIS (EF-25) trial evaluating the efficacy and safety of tumor treating fields therapy following stereotactic radiosurgery in patients with mutation-negative non–small cell lung cancer (NSCLC) and brain metastases. Tumor treating fields therapy prolongs time to intracranial disease progression and may postpone whole-brain radiation therapy without declines in quality of life and cognition (Abstract 2008).

Prostate Cancer
Genomics/Genetics

Alicia Morgans, MD, MPH, and Susan Halabi, PhD, on Prostate Cancer: New Findings on Classifying Patients Into Risk Groups

Alicia Morgans, MD, MPH, of Dana-Farber Cancer Institute, and Susan Halabi, PhD, of the Duke Cancer Institute and Duke University School of Medicine, discuss a clinical-genetic model that identified novel circulating tumor DNA alterations that are prognostic of overall survival and may help to classify patients with metastatic castration-resistant prostate cancer into risk groups useful for selecting trial participants (Abstract 5007).

Multiple Myeloma

Suzanne Trudel, MD, on Multiple Myeloma: Results From the DREAMM-8 Study of Treatments After Relapse

Suzanne Trudel, MD, of Canada’s Princess Margaret Cancer Centre, discusses phase III findings showing that, in patients with relapsed or refractory multiple myeloma who had one or more prior lines of treatment, belantamab mafodotin-blmf plus pomalidomide and dexamethasone improved progression-free survival and showed a favorable overall survival trend compared with pomalidomide plus bortezomib and dexamethasone.

Advertisement

Advertisement




Advertisement